{"organizations": [], "uuid": "74f7c0e3cbbfaee0c578119ece6595f692a17f1f", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180515.html", "section_title": "Archive News &amp; Video for Tuesday, 15 May 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-us-fda-approves-retacrit-as-biosim/brief-u-s-fda-approves-retacrit-as-biosimilar-to-epogen-procrit-for-treatment-of-anemia-idUSFWN1SM17B", "country": "US", "domain_rank": 408, "title": "BRIEF-U.S. FDA Approves Retacrit As Biosimilar To Epogen/Procrit For Treatment Of Anemia", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.999, "site_type": "news", "published": "2018-05-15T23:54:00.000+03:00", "replies_count": 0, "uuid": "74f7c0e3cbbfaee0c578119ece6595f692a17f1f"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-us-fda-approves-retacrit-as-biosim/brief-u-s-fda-approves-retacrit-as-biosimilar-to-epogen-procrit-for-treatment-of-anemia-idUSFWN1SM17B", "ord_in_thread": 0, "title": "BRIEF-U.S. FDA Approves Retacrit As Biosimilar To Epogen/Procrit For Treatment Of Anemia", "locations": [], "entities": {"persons": [], "locations": [{"name": "hospira", "sentiment": "none"}], "organizations": [{"name": "fda", "sentiment": "negative"}, {"name": "u.s. food and drug administration", "sentiment": "negative"}, {"name": "reuters", "sentiment": "negative"}, {"name": "treatment of anemia", "sentiment": "negative"}, {"name": "pfizer", "sentiment": "none"}, {"name": "thomson reuters trust principles", "sentiment": "none"}, {"name": "inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 15 (Reuters) - The U.S. Food and Drug Administration:\n* SAYS APPROVED RETACRIT AS BIOSIMILAR TO EPOGEN/PROCRIT FOR TREATMENT OF ANEMIA\n* SAYS GRANTED APPROVAL OF RETACRIT TO HOSPIRA INC, A PFIZER COMPANY\n* SAYS AS WITH EPOGEN/PROCRIT, RETACRIT CONTAINS BOXED WARNING ABOUT INCREASED RISKS OF DEATH, HEART PROBLEMS, STROKE, TUMOR GROWTH OR RECURRENCE\n* SAYS APPROVAL OF RETACRIT FOR TREATMENT OF ANEMIA CAUSED BY CHRONIC KIDNEY DISEASE, CHEMOTHERAPY, OR USE OF ZIDOVUDINE IN PATIENTS WITH HIV INFECTION\n* SAYS RETACRIT HAS BEEN APPROVED AS A BIOSIMILAR, NOT AS AN INTERCHANGEABLE PRODUCT Further company coverage:\nOur Standards: The Thomson Reuters Trust Principles. ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://instagram.com/reuters/"], "published": "2018-05-15T23:54:00.000+03:00", "crawled": "2018-05-16T19:02:11.004+03:00", "highlightTitle": ""}